IL187168A - Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses - Google Patents

Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses

Info

Publication number
IL187168A
IL187168A IL187168A IL18716807A IL187168A IL 187168 A IL187168 A IL 187168A IL 187168 A IL187168 A IL 187168A IL 18716807 A IL18716807 A IL 18716807A IL 187168 A IL187168 A IL 187168A
Authority
IL
Israel
Prior art keywords
nanobedis
proteins
preparation
methods
von willebrand
Prior art date
Application number
IL187168A
Other languages
English (en)
Hebrew (he)
Other versions
IL187168A0 (en
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of IL187168A0 publication Critical patent/IL187168A0/en
Publication of IL187168A publication Critical patent/IL187168A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL187168A 2005-05-20 2007-11-05 Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses IL187168A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68347405P 2005-05-20 2005-05-20
PCT/EP2006/004773 WO2006122825A2 (en) 2005-05-20 2006-05-19 Single domain vhh antibodies against von willebrand factor

Publications (2)

Publication Number Publication Date
IL187168A0 IL187168A0 (en) 2008-02-09
IL187168A true IL187168A (en) 2015-05-31

Family

ID=37431613

Family Applications (2)

Application Number Title Priority Date Filing Date
IL187168A IL187168A (en) 2005-05-20 2007-11-05 Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
IL208607A IL208607A0 (en) 2005-05-20 2010-10-11 Improved nanobodiestm for the treatment of aggregation-mediated disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL208607A IL208607A0 (en) 2005-05-20 2010-10-11 Improved nanobodiestm for the treatment of aggregation-mediated disorders

Country Status (28)

Country Link
US (3) US7807162B2 (Direct)
EP (4) EP3243839A1 (Direct)
JP (1) JP4986997B2 (Direct)
KR (1) KR101414438B1 (Direct)
CN (1) CN101213214B (Direct)
AU (1) AU2006249090B2 (Direct)
BE (1) BE2019C503I2 (Direct)
BR (1) BRPI0609797B8 (Direct)
CA (2) CA2608873C (Direct)
CY (2) CY1122579T1 (Direct)
DK (1) DK2444424T3 (Direct)
ES (2) ES2852423T3 (Direct)
FR (1) FR19C1005I2 (Direct)
HU (2) HUE039846T2 (Direct)
IL (2) IL187168A (Direct)
LT (2) LT2444424T (Direct)
LU (1) LUC00099I2 (Direct)
MX (1) MX2007014564A (Direct)
NL (1) NL300966I2 (Direct)
NO (3) NO20076475L (Direct)
NZ (1) NZ563392A (Direct)
PL (2) PL2444424T3 (Direct)
PT (2) PT2444424T (Direct)
RU (1) RU2433139C2 (Direct)
SI (1) SI2444424T1 (Direct)
TR (1) TR201815552T4 (Direct)
WO (1) WO2006122825A2 (Direct)
ZA (1) ZA200709570B (Direct)

Families Citing this family (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US9320792B2 (en) * 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
MXPA05006043A (es) 2003-01-10 2006-01-30 Ablynx Nv Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
RU2398882C2 (ru) 2004-07-22 2010-09-10 Эрасмус Юниверсити Медикал Сентр Роттердам СПОСОБ ПОЛУЧЕНИЯ АНТИГЕН-СВЯЗЫВАЮЩЕГО ДОМЕНА Vh ИСПОЛЬЗОВАНИЕ
SI1836500T1 (sl) 2005-01-14 2010-11-30 Ablynx Nv Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
TR201815552T4 (tr) 2005-05-20 2018-11-21 Ablynx Nv Agregasyon ile ilgili hastalıkların tedavisine yönelik iyileştirilmiş nanoantikorlar (TM).
WO2008049881A2 (en) * 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
JP2010507624A (ja) * 2006-10-27 2010-03-11 アブリンクス エン．ヴェー． ポリペプチド及びタンパク質の鼻内送達
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
CA2672965C (en) 2006-12-19 2018-02-06 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
CA2678218A1 (en) * 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
WO2008142164A2 (en) 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2009004066A2 (en) 2007-07-03 2009-01-08 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
JP2011504740A (ja) * 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
CN101932593B (zh) * 2008-01-29 2014-08-20 埃博灵克斯股份有限公司 稳定蛋白和多肽的方法
AU2009221106A1 (en) * 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
US20110158996A1 (en) * 2008-03-21 2011-06-30 Ablynx N.V. Von willebrand factor specific binders and methods of use therefor
CN102056945A (zh) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 针对Notch途径的单可变结构域
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
AU2009273251B2 (en) 2008-07-22 2014-12-18 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
US20110311515A1 (en) * 2009-01-14 2011-12-22 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
AU2010243551B2 (en) 2009-04-30 2015-03-26 Ablynx Nv Method for the production of domain antibodies
EP2451839B1 (en) 2009-07-10 2020-04-22 Ablynx N.V. Method for the production of variable domains
US9884117B2 (en) 2009-09-03 2018-02-06 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
WO2011067160A1 (en) 2009-12-01 2011-06-09 Ablynx Nv Von willebrand factor specific binding agents and uses thereof
EP2513145B1 (en) 2009-12-14 2018-01-24 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
JP2013518853A (ja) 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
PT2533761T (pt) 2010-02-11 2019-06-17 Ablynx Nv Métodos e composições para a preparação de aerossóis
EP2533814A2 (en) 2010-02-11 2012-12-19 Ablynx N.V. Delivery of immunoglobulin variable domains and constructs thereof
MX2012009460A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Int Polipeptidos biparatopicos de union abeta.
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
KR20130080790A (ko) 2010-05-20 2013-07-15 아블린쓰 엔.브이. Ｈｅｒ３와 관련된 생물학적 물질들
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
NO2632946T3 (Direct) 2010-10-29 2018-05-05
EA202092589A3 (ru) 2010-11-08 2021-06-30 Аблинкс Н.В. Cxcr2-связывающие полипептиды
US9468679B2 (en) 2011-03-28 2016-10-18 Ablynx N.V. Method for producing solid formulations comprising immunoglobulin single variable domains
AU2012234284B2 (en) 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
CN103732625A (zh) 2011-05-27 2014-04-16 埃博灵克斯股份有限公司 使用rankl结合肽抑制骨质吸收
SI2723769T2 (sl) 2011-06-23 2022-09-30 Ablynx Nv Tehnike za napovedovanje, zaznavanje in zmanjševanje nespecifične motnje proteina v testih, ki vključujejo domene imunoglobulina z eno spremenljivko
EP4350345A3 (en) 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
PH12013502669B1 (en) 2011-06-23 2018-08-10 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
AU2012273928A1 (en) 2011-06-23 2014-02-06 Ablynx Nv Immunoglobulin single variable domains directed against IgE
MX2014001883A (es) * 2011-08-17 2014-05-27 Glaxo Group Ltd Proteinas y peptidos modificados.
WO2013036130A1 (en) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
EP3311837A1 (en) 2011-09-23 2018-04-25 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
DE102011121237A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
DE102011121238A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
AU2013265665B2 (en) 2012-05-24 2017-10-26 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
KR20150023679A (ko) * 2012-06-08 2015-03-05 그렌마크 파머수티칼스 에스. 아. 아미노산 치환을 갖는 인간화된 항-TrkA 항체
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
PT2951201T (pt) 2013-01-30 2018-01-09 Univ Brussel Vrije Novos polipéptidos quiméricos para rastreamento e fins de descoberta de fármacos
ES2745772T3 (es) 2013-02-05 2020-03-03 Vib Vzw Agentes de unión al receptor muscarínico de la acetilcolina y usos de los mismos
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
AU2014229952B2 (en) 2013-03-15 2018-10-04 Vib Vzw Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
WO2014197885A2 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
EP3008085A4 (en) * 2013-06-13 2017-05-10 Biogen MA Inc. Anti-factor viii antibodies or uses thereof
WO2015121092A1 (en) 2014-01-30 2015-08-20 Vib Vzw Opioid receptor binding agents and uses thereof
ES2924393T3 (es) * 2014-04-16 2022-10-06 Inst Nat Sante Rech Med Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
RU2746738C2 (ru) 2014-05-16 2021-04-20 Аблинкс Нв Улучшенные вариабельные домены иммуноглобулина
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2955554C (en) 2014-07-22 2022-07-05 Vib Vzw Methods to select for agents that stabilize protein complexes
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
CA2971278C (en) 2014-12-19 2023-09-19 Ablynx N.V. Cysteine linked nanobody dimers
EP3277316B1 (en) 2015-04-02 2025-03-05 Ablynx N.V. Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
HRP20240971T1 (hr) 2015-05-13 2024-10-25 Ablynx Nv Polipeptidi za regruitiranje t-stanica na temelju cd3 reaktivnosti
RS66859B1 (sr) 2015-05-13 2025-06-30 Ablynx Nv Polipeptidi koji regrutuju t-ćelije na bazi tcr-alfa/beta reaktivnosti
WO2016186994A1 (en) * 2015-05-15 2016-11-24 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of thrombotic microangiopathy
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
SI3316885T1 (sl) 2015-07-01 2021-09-30 Immunomedics, Inc. Imunokonjugati protitelo-SN-38 z linkerjem CL2A
NZ739392A (en) 2015-07-31 2019-10-25 Medimmune Ltd Methods for treating hepcidin-mediated disorders
NO2768984T3 (Direct) 2015-11-12 2018-06-09
WO2017080850A1 (en) 2015-11-13 2017-05-18 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
CN109071639B (zh) * 2015-11-18 2022-07-08 默沙东公司 Pd1/ctla4结合剂
CR20180279A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de ctla4
CN108473564B (zh) 2015-11-18 2022-04-08 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
PE20181956A1 (es) 2015-11-27 2018-12-17 Ablynx Nv Polipeptidos que inhiben cd40l
JP7096458B2 (ja) * 2016-01-26 2022-07-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗ｖｗｆ ｄ’ｄ３単一ドメイン抗体及びそれを含むポリペプチド
CA3022697A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
AR108468A1 (es) * 2016-05-13 2018-08-22 Medimmune Llc POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
RS67145B1 (sr) 2016-05-20 2025-09-30 Harpoon Therapeutics Inc Proteini sa jednolančanim varijabilnim fragmentom koji vezuju cd3
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CA3029133C (en) 2016-06-23 2024-04-30 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
JP7222888B2 (ja) 2016-11-16 2023-02-15 アブリンクス エン．ヴェー． Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
CN110198955A (zh) 2016-11-23 2019-09-03 哈普恩治疗公司 前列腺特异性膜抗原结合蛋白质
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
CA3050575A1 (en) 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
KR20230165374A (ko) 2017-01-17 2023-12-05 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
KR20250029283A (ko) 2017-02-01 2025-03-04 노보 노르디스크 에이/에스 이뇨제 내성의 치료
CN110573604A (zh) 2017-02-28 2019-12-13 非营利性组织佛兰芒综合大学生物技术研究所 用于口服蛋白质递送的工具和方法
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
MX2019011702A (es) 2017-03-31 2019-11-01 Ablynx Nv Ensayos de inmunogenicidad mejorados.
US10865238B1 (en) * 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2018206734A1 (en) 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
CN110891974B (zh) 2017-05-12 2021-08-06 哈普恩治疗公司 间皮素结合蛋白质
AU2018265860B2 (en) 2017-05-12 2022-08-11 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
HRP20241562T1 (hr) 2017-06-02 2025-01-31 Merck Patent Gmbh Adamts vezujući imunoglobulini
JP7249961B2 (ja) 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
SG10202113337YA (en) * 2017-06-02 2021-12-30 Ablynx Nv Aggrecan binding immunoglobulins
JP2020521804A (ja) 2017-06-02 2020-07-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｍｍｐ１３結合免疫グロブリン
CN111108126B (zh) 2017-07-19 2024-04-26 非营利性组织佛兰芒综合大学生物技术研究所 血清白蛋白结合剂
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CR20200196A (es) 2017-10-13 2020-06-05 Harpoon Therapeutics Inc Proteínas trispecìficas y mètodos de uso
KR20200091400A (ko) 2017-10-31 2020-07-30 브이아이비 브이지더블유 신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도
US20200199206A1 (en) * 2017-12-08 2020-06-25 AC Thera, LLC Bacterial toxin-neutralizing nanobodies and methods of making and using the same
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
CA3090321A1 (en) 2018-02-05 2019-08-08 Stichting Vu Inverse agonistic anti-us28 antibodies
CN111670202A (zh) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
TW202000238A (zh) 2018-02-26 2020-01-01 比利時商艾伯林克斯公司 編碼肽連接子之經改良核苷酸序列
JP2021514649A (ja) 2018-03-01 2021-06-17 ブレイエ・ユニバージテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｔｅｉｔ Ｂｒｕｓｓｅｌ ヒトｐｄ−ｌ１結合免疫グロブリン
CA3095080A1 (en) 2018-03-27 2019-10-03 Coen MAAS Targeted thrombolysis for treatment of microvascular thrombosis
SG11202011330PA (en) 2018-05-14 2020-12-30 Harpoon Therapeutics Inc Binding moiety for conditional activation of immunoglobulin molecules
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
AU2020253685B2 (en) 2019-04-02 2025-09-04 Nykode Therapeutics ASA Immune-stimulatory compositions and use thereof
CN114041056A (zh) 2019-04-29 2022-02-11 康福治疗有限公司 用于跨膜蛋白尤其是gpcr的筛选方法和测定
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
MA55809B1 (fr) 2019-05-01 2025-12-31 Novo Nordisk A/S Formulations d'anticorps anti-il-6
CN114245806A (zh) 2019-05-14 2022-03-25 哈普恩治疗公司 EpCAM结合蛋白及使用方法
US12472254B2 (en) 2019-05-28 2025-11-18 Vib Vzw CD8+ T-cells lacking plexins and their application in cancer treatment
US20220220197A1 (en) 2019-05-28 2022-07-14 Vib Vzw Cancer Treatment by Targeting Plexins in the Immune Compartment
US20220324947A1 (en) 2019-08-05 2022-10-13 Stichting Vu Identification and Elimination of HCMV-Infected Cells
WO2021039574A1 (ja) * 2019-08-23 2021-03-04 株式会社カネカ Ｏ結合型糖鎖修飾が抑制された重鎖抗体
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
US20220380456A1 (en) 2019-10-21 2022-12-01 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
AU2020384953A1 (en) 2019-11-11 2022-06-23 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
IL295892A (en) 2020-02-25 2022-10-01 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
US20230279115A1 (en) 2020-04-22 2023-09-07 Mabwell (shanghai) Bioscience Co., Ltd. Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2021258160A1 (en) * 2020-06-26 2021-12-30 Monash University Anti-vwf antibodies and uses thereof
US20230265211A1 (en) * 2020-06-29 2023-08-24 Inserm (Institut National De La Santé Et De Ls Recherche Médicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
AR122933A1 (es) 2020-07-10 2022-10-19 Novo Nordisk As Métodos para tratar la enfermedad cardiovascular
CA3196737A1 (en) 2020-09-24 2022-03-31 Massimiliano Mazzone Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
IL301581A (en) 2020-09-25 2023-05-01 Ablynx Nv Polypeptides comprising single immunoglobulin variable sites targeting 13-IL and OX40L
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022133110A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Epcam binding molecules and uses thereof
CA3205463A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Cea6 binding molecules and uses thereof
CA3205466A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Mesothelin binding molecules and uses thereof
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
WO2022133050A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Gpc3 binding molecules and uses thereof
US20240084039A1 (en) * 2020-12-23 2024-03-14 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2022136693A1 (en) * 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
WO2022136647A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Human ccr8 binders
WO2022136650A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Murine cross-reactive human ccr8 binders
CA3206124A1 (en) 2020-12-24 2022-06-30 Vib Vzw Non-blocking human ccr8 binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
AU2022216460A1 (en) 2021-02-05 2023-09-21 Universiteit Gent Sarbecovirus binders
WO2022175392A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
WO2022175532A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
WO2022216157A1 (en) 2021-04-09 2022-10-13 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US20240287501A1 (en) 2021-06-23 2024-08-29 Vib Vzw Means and Methods for Selection of Specific Binders
WO2023274183A1 (zh) 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
US20250336476A1 (en) * 2021-07-12 2025-10-30 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and sytems for nanobody humanization
US20240327525A1 (en) 2021-07-30 2024-10-03 Vib Vzw Cation-Independent Mannose-6-Phosphate Receptor Binders For Targeted Protein Degradation
US20240343803A1 (en) 2021-07-30 2024-10-17 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof
ES3037735T3 (en) 2021-08-03 2025-10-06 Univ Wageningen Argonaute-based nucleic acid detection system
US20250026844A1 (en) 2021-12-03 2025-01-23 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-bcma nanobody and use thereof
KR20240122867A (ko) 2021-12-17 2024-08-13 아블린쓰 TCRαβ, CD33, 및 CD123을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
WO2023125888A1 (zh) 2021-12-31 2023-07-06 山东先声生物制药有限公司 一种gprc5d抗体及其应用
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
EP4476250A1 (en) 2022-02-07 2024-12-18 Vib Vzw Engineered stabilizing aglycosylated fc-regions
EP4508082A1 (en) 2022-04-13 2025-02-19 Vib Vzw An ltbr agonist in combination therapy against cancer
US20250313611A1 (en) 2022-05-18 2025-10-09 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
CN119317648A (zh) 2022-06-06 2025-01-14 山东先声生物制药有限公司 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
EP4551600A1 (en) 2022-07-04 2025-05-14 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
JP7459354B2 (ja) 2022-07-08 2024-04-01 ノヴォ ノルディスク アー／エス ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物
WO2024013402A1 (en) 2022-07-15 2024-01-18 Gadeta B.V. Novel soluble gamma t-cell (or soluble delta t-cell) receptor chains (or soluble gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
IL318486A (en) 2022-07-27 2025-03-01 Ablynx Nv Polypeptides bind to a specific epitope of the neonatal Fc receptor
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
EP4612180A1 (en) 2022-10-31 2025-09-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4620974A1 (en) 2022-11-15 2025-09-24 Oricell Therapeutics Co., Ltd. Anti-afp/hla02 tcr-like antibody and use thereof
WO2024105091A1 (en) 2022-11-15 2024-05-23 Imec Vzw Method and system for droplet manipulation
US20240200085A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
EP4634232A1 (en) * 2022-12-15 2025-10-22 Institut National de la Santé et de la Recherche Médicale Single-domain antibody targeting von wilebrand factor a3-domain
EP4638472A1 (en) 2022-12-19 2025-10-29 UMC Utrecht Holding B.V. Btn2a1 binding peptide
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024165710A1 (en) 2023-02-09 2024-08-15 Seni-Preps B.V. Immunoglobulin single variable domains that inhibit urease and use thereof
AU2024221136A1 (en) 2023-02-17 2025-10-02 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
US20240344078A1 (en) 2023-03-14 2024-10-17 Aarhus Universitet Genetically altered nfr5 receptor kinases
EP4688849A1 (en) 2023-04-03 2026-02-11 Vib Vzw Blood-brain barrier crossing antibodies
WO2024231348A1 (en) 2023-05-11 2024-11-14 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024251826A1 (en) 2023-06-05 2024-12-12 Vib Vzw Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251981A1 (en) 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024261344A1 (en) 2023-06-23 2024-12-26 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
GB202314424D0 (en) 2023-09-20 2023-11-01 Cambridge Entpr Ltd A conjugate
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
TW202542180A (zh) 2023-12-22 2025-11-01 比利時商艾伯霖克斯公司 用於位點特異性胺軛合的基於蛋白質的載體
TW202543670A (zh) 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 用於核內投予之基於蛋白質的接合載劑
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025167664A1 (zh) * 2024-02-07 2025-08-14 原启生物科技(上海)有限责任公司 Ror1抗原结合蛋白及其用途
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
US20260007757A1 (en) 2024-06-18 2026-01-08 Ablynx Nv Antibody-recruiting molecules
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use
WO2026027659A1 (en) 2024-07-31 2026-02-05 Seni-Preps B.V. Improved immunoglobulin single variable domains that inhibit urease and use thereof

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5238919A (en) 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
ES2073394T3 (es) 1987-06-10 1995-08-16 Dana Farber Cancer Inst Inc Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares.
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0590060T3 (da) 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
ATE348175T1 (de) 1992-07-17 2007-01-15 Dana Farber Cancer Inst Inc Method eder intrazellularen bindung von zielgerichteten molekülen
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
WO1994013806A1 (en) 1992-12-11 1994-06-23 The Dow Chemical Company Multivalent single chain antibodies
ATE167396T1 (de) 1993-02-22 1998-07-15 Alza Corp Mittel zur oralen gabe von wirkstoffen
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
GB9311454D0 (en) 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
WO1994029457A2 (en) 1993-06-09 1994-12-22 Unilever N.V. Process for producing fusion proteins comprising scfv fragments by a transformed mould
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
WO1995007463A1 (en) 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5916805A (en) 1994-11-30 1999-06-29 Ajinomoto Co., Inc. Antithrombotic agent and anti-von Willebrand factor monoclonal antibody
WO1996022307A1 (en) 1995-01-19 1996-07-25 The Research Foundation Of State University Of New York Genes encoding an insect calcium channel
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
ES2139329T3 (es) 1995-09-22 2000-02-01 Bioimage A S Nuevas variantes de la proteina fluorescente verde, gfp.
AU2507397A (en) 1996-04-04 1997-10-29 Unilever Plc Multivalent and multispecific antigen-binding protein
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
DE69738166T2 (de) 1996-06-27 2008-06-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1015480A2 (en) 1997-08-18 2000-07-05 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US5895466A (en) 1997-08-19 1999-04-20 At&T Corp Automated natural language understanding customer service system
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
US20020155604A1 (en) 1998-02-19 2002-10-24 Jeffrey A. Ledbetter Compositions and methods for regulating lymphocyte activation
ATE535154T1 (de) 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
ATE232298T1 (de) 1998-07-06 2003-02-15 Euroscreen Sa Bioluminenztest für agonisten oder antagonisten eines kalzium-gekuppelten-rezeptors
US6228360B1 (en) 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US6251393B1 (en) 1998-10-23 2001-06-26 The Brigham And Women's Hospital, Inc. Conformation-specific anti-von Willebrand Factor antibodies
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
BR9916765A (pt) 1999-01-05 2001-09-25 Unilever Nv Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico
EP1144616B2 (en) 1999-01-19 2009-01-14 Unilever Plc Method for producing antibody fragments
JP2002535993A (ja) 1999-02-05 2002-10-29 リイクスニフェルシタイト ライデン 組換え体細胞における代謝物の生合成を変調する方法
US6419934B1 (en) 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
DE1100895T1 (de) 1999-03-15 2001-09-06 The University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
BR0009866A (pt) 1999-04-22 2002-01-08 Unilever Nv Método de inibição de infecção viral, uso de uma proteìna de ligação de antìgeno monovalente, produto alimentìcio, composição farmacêutica ou cosmética, proteìna de ligação de antìgeno monovalente, sequência de nucleotìdeos, vetor de expressão, célula hospedeira, e, métodos de seleção e de indentificação de uma proteìna de ligação de antìgeno
JP2003508031A (ja) 1999-06-18 2003-03-04 スィーヴィー セラピューティクス インコーポレイテッド Ａｔｐ結合カセット輸送体蛋白質ａｂｃ１を用いるコレステロール流出を増加させｈｄｌを上昇させるための組成物および方法
WO2001002853A2 (en) 1999-07-05 2001-01-11 K.U. Leuven Research & Development DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY
EP1198572A2 (en) 1999-08-02 2002-04-24 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
DE60031441T2 (de) 1999-11-29 2007-08-30 Unilever N.V. Immobilisierung von proteinen mit hilfe eines polypeptidsegments
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
ATE428733T1 (de) 2000-03-14 2009-05-15 Unilever Nv Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
EP1343820A4 (en) 2000-10-13 2005-09-14 Uab Research Foundation HUMANE SINGLE CHAIN ANTI EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
GB0031448D0 (en) 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
DE10105526B4 (de) 2001-02-07 2004-12-23 Robert Bosch Gmbh Verfahren zur Herstellung einer Klappenanordnung
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
JP2004538324A (ja) 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US20050136056A1 (en) 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
AU2003284891A1 (en) 2002-10-23 2004-05-13 Ludwig Institute For Cancer Research A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
AU2003283137B8 (en) 2002-11-08 2010-07-29 Ablynx N.V. Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
MXPA05006043A (es) * 2003-01-10 2006-01-30 Ablynx Nv Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
AU2003283136A1 (en) 2003-11-07 2005-05-26 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070084170A (ko) * 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
SI1836500T1 (sl) 2005-01-14 2010-11-30 Ablynx Nv Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
TR201815552T4 (tr) 2005-05-20 2018-11-21 Ablynx Nv Agregasyon ile ilgili hastalıkların tedavisine yönelik iyileştirilmiş nanoantikorlar (TM).
WO2008049881A2 (en) 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
US20110158996A1 (en) 2008-03-21 2011-06-30 Ablynx N.V. Von willebrand factor specific binders and methods of use therefor

Also Published As

Publication number Publication date
BRPI0609797B8 (pt) 2021-05-25
IL208607A0 (en) 2010-12-30
NO345342B1 (no) 2020-12-21
ES2852423T3 (es) 2021-09-13
FR19C1005I1 (fr) 2019-03-22
JP4986997B2 (ja) 2012-07-25
BRPI0609797A2 (pt) 2010-04-27
ZA200709570B (en) 2008-10-29
EP2444424B1 (en) 2018-08-08
WO2006122825A3 (en) 2007-10-04
MX2007014564A (es) 2008-02-07
HUE039846T2 (hu) 2019-02-28
US20100330084A1 (en) 2010-12-30
AU2006249090A1 (en) 2006-11-23
NL300966I1 (nl) 2019-02-13
AU2006249090A8 (en) 2006-11-23
KR20080023301A (ko) 2008-03-13
BRPI0609797B1 (pt) 2018-07-03
EP3415535B1 (en) 2020-12-09
IL187168A0 (en) 2008-02-09
HUS1900005I1 (hu) 2019-03-28
NO20076475L (no) 2008-02-18
PT3415535T (pt) 2021-02-02
US7807162B2 (en) 2010-10-05
PL3415535T3 (pl) 2021-06-14
WO2006122825A2 (en) 2006-11-23
NO2021020I1 (no) 2021-05-20
CY1122579T1 (el) 2020-05-29
CA2608873C (en) 2017-04-25
FR19C1005I2 (fr) 2020-01-31
CA2608873A1 (en) 2006-11-23
BE2019C503I2 (Direct) 2025-12-10
LTPA2019504I1 (lt) 2020-07-27
EP2444424A1 (en) 2012-04-25
JP2008539775A (ja) 2008-11-20
WO2006122825A9 (en) 2007-03-29
PT2444424T (pt) 2018-11-09
LT2444424T (lt) 2018-10-25
DK2444424T3 (en) 2018-12-03
ES2694247T3 (es) 2018-12-19
TR201815552T4 (tr) 2018-11-21
KR101414438B1 (ko) 2014-07-10
AU2006249090B2 (en) 2012-08-23
EP3415535A1 (en) 2018-12-19
EP3243839A1 (en) 2017-11-15
LTC2444424I2 (lt) 2020-07-27
US20130136736A1 (en) 2013-05-30
RU2433139C2 (ru) 2011-11-10
NL300966I2 (nl) 2019-04-11
NO20190279A1 (no) 2007-12-17
CY2019006I2 (el) 2020-05-29
US8372398B2 (en) 2013-02-12
US20100022452A1 (en) 2010-01-28
EP2007814A2 (en) 2008-12-31
CN101213214B (zh) 2014-06-25
RU2007147381A (ru) 2009-06-27
LUC00099I1 (Direct) 2019-02-12
SI2444424T1 (sl) 2018-10-30
CN101213214A (zh) 2008-07-02
CY2019006I1 (el) 2020-05-29
PL2444424T3 (pl) 2019-01-31
LUC00099I2 (Direct) 2019-12-27
NZ563392A (en) 2009-12-24
CA2960105A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
BRPI0508259A (pt) derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
LTC1641823I2 (lt) GLP-1 analogo sulieti baltymai
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
DE60329983D1 (de) Wachsestersynthase-dna-sequenz, protein und verwendungen davon
IL164021A (en) Anti-alphavbeta6 antibodies and pharmaceutical compositions containing the same
EP1490094A4 (en) ANTIBODY FUSION PROTEINS AS EFFECTIVE ADJUVANTS FOR PROTEIN VACCINATION
BRPI0507118A (pt) polipeptìdeos de interferon humano modificado e seus usos
IL191759A (en) Ganaxolone formulations and methods for the making and use thereof
NO20055774D0 (no) Flytende stabiliserte proteinformuleringer i belagte farmasoytiske beholdere
NO20052285D0 (no) Faste, partikkelformige, antifungale preparater for farmasoytisk anvendelse
ATE555809T1 (de) Pharmezeutische anti-tnf-alpha antikörper formulierung
IL184288A0 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
NO20040249L (no) Blodgruppeantigenfusjonspolypeptider og fremgangsmater for deres anvendelse
IS8422A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun þeirra
ATE389398T1 (de) Neue azabicyclische derivate, herstellungsverfahren dafür und sie enthaltende pharmazeutische zusammensetzungen
IS8219A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun
NO20052794D0 (no) Antibakterielle indolonoksazolidinoner intermediater for fremstilling av disse og farmasoytiske prepareter inneholdende disse
IL223938B (en) Compositions for infusion containing ex-vivo prepared t-cells and methods for the preparation thereof
WO2006082304A3 (fr) Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
NO20042890L (no) Farmasoytiske preparater og fremgangsmate for fremstilling derav
EP1461416A4 (en) IMPROVED PROTEINS AND METHOD FOR THEIR USE
EP1786431A4 (en) IMPROVED PHOTOSENSITIZER FORMULATIONS AND THEIR USE

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed